trimethyl ester of 4-carboxyl-6-methoxyphthalic acid | 43136-37-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: trimethyl ester of 4-carboxyl-6-methoxyphthalic acid
• 英文别名: methyl 6-methoxy-1,2,4-benzenetricarboxylate；6-methoxy-benzene-1,2,4-tricarboxylic acid trimethyl ester；6-Methoxy-benzol-1,2,4-tricarbonsaeure-trimethylester；6-Methoxytrimellitinsaeure-trimethylester；Trimethyl 6-methoxybenzene-1,2,4-tricarboxylate
• CAS: 43136-37-4
• 化学式: C₁₃H₁₄O₇
• 分子量: 282.25
• InChiKey: QMUQUSACKJWSSJ-UHFFFAOYSA-N

物化性质

• 熔点：
  145 °C
• 沸点：
  375.4±37.0 °C(Predicted)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  88.1
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-methoxy-1,2,4-benzenetricarboxylic acid 生成 trimethyl ester of 4-carboxyl-6-methoxyphthalic acid
  参考文献：
  名称：

  233.马来酸酐的新合成

  摘要：

  DOI：

  10.1039/jr9460001052

文献信息

• Functionalized drugs and polymers derived therefrom
  申请人：Bezwada S. Rao

  公开号：US20060172983A1

  公开（公告）日：2006-08-03

  Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.

  从中选择的化合物：其中DRUG-OH，DRUG-COOH和DRUG-NH2是生物活性化合物；每个X独立地从—CH2COO—（乙二酸基团），—CH(CH3)COO—（乳酸基团），—CH2CH2OCH2COO—（二氧杂环己酮基团），—CH2CH2CH2CH2CH2COO—（己内酯基团），—(CH2)yCOO—中选择，其中y为2-4或6-24和—(CH2CH2O)zCH2COO—，其中z为2-24；每个Y独立地从—COCH2O—（乙二酸酯基团），—COCH(CH3)O—（乳酸酯基团），—COCH2OCH2CH2O—（二氧杂环己酮酯基团），—COCH2CH2CH2CH2CH2O—（己内酯酯基团），—CO(CH2)mO—，其中m为2-4或6-24和—COCH2O(CH2CH2O)n—，其中n为2-24；R′为氢，苄基或烷基，烷基可以是直链或支链；p为1-6。还披露了多功能化合物和药物二聚体、寡聚体和聚合物。
• FUNCTIONALIZED PHENOLIC COMPOUNDS AND POLYMERS THEREFROM
  申请人：Bezwada Rao S.

  公开号：US20090170927A1

  公开（公告）日：2009-07-02

  The present invention relates to compounds of formula I, which are functionalized phenolic compounds, and polymers formed from the same. Ar—[O—(X) p —R′] q I Polymers formed from the functionalized phenolics are expected to have controllable degradation profiles, enabling them to release an active component over a desired time range. The polymers are also expected to be useful in a variety of medical applications.

  本发明涉及公式I的化合物，这些化合物是官能化酚类化合物，以及由它们形成的聚合物。从官能化酚类化合物形成的聚合物预计具有可控的降解特性，使它们能够在所需的时间范围内释放活性成分。这些聚合物还预计在各种医疗应用中有用。
• Chemistry of toromycin.
  作者：SATOSHI HORII、HIROSHI FUKASE、EIJI MIZUTA、KAZUNORI HATANO、KOMEI MIZUNO

  DOI：10.1248/cpb.28.3601

  日期：——

  Chemical degradation and spectral studies on toromycin, an antibiotic isolated from Streptomyces collinus subsp. albescens, showed that toromycin is a polycyclic aromatic hydrocarbon having a C-glycosyl group at C-4, a vinyl group at C-8, two methoxyl groups at C-10 and C-12, and a phenolic hydroxyl group at C-1 of 6-oxo-6H-benzo [d] naphtho-[1, 2-b] pyran (1).

  对从 Streptomyces collinus subsp. albescens 分离出的抗生素 Toromycin 进行的化学降解和光谱研究表明，Toromycin 是一种多环芳香烃，其 C-4 位有一个 C-糖基，C-8 位有一个乙烯基，C-10 和 C-12 位有两个甲氧基，C-1 位有一个 6-oxo-6H-benzo [d] naphtho-[1, 2-b] pyran (1) 的酚羟基。
• On the structure, chemistry, and ¹³C nuclear magnetic resonance of ravidomycin
  作者：John A. Findlay、Jia-Sen Liu、Lajos Radics

  DOI：10.1139/v83-058

  日期：1983.2.1

  Full spectral details in support of the earlier proposed structure 1a for the antitumor antibiotic ravidomycin are presented together with an account of chemical degradation products. A complete corroboration of structure is provided by cross correlation of ¹H and ¹³C nmr for ravidomycin and its diacetate 1b.

  在支持先前提出的抗肿瘤抗生素拉维多霉素结构1a的全光谱细节与化学降解产物的描述一起呈现。通过拉维多霉素及其二乙酸盐1b的1H和13C NMR的交叉相关提供了结构的完整证实。
• FUNCTIONALIZED DRUGS AND POLYMERS THEREFROM
  申请人：Bezwada Rao S.

  公开号：US20100152272A1

  公开（公告）日：2010-06-17

  Compounds selected from: where DRUG-OH, DRUG-COOH and DRUG-NH 2 are biologically active compounds; each X is independently selected from —CH 2 COO— (glycolic acid moiety), —CH(CH 3 )COO— (lactic acid moiety), —CH 2 CH 2 OCH 2 COO— (dioxanone moiety), —CH 2 CH 2 CH 2 CH 2 CH 2 COO— (caprolactone moiety), —(CH 2 ) y COO—, where y is 2-4 or 6-24 and —(CH 2 CH 2 O) z CH 2 COO—, where z is 2-24; each Y is independently selected from —COCH 2 O— (glycolic ester moiety), —COCH(CH 3 )O— (lactic ester moiety), —COCH 2 OCH 2 CH 2 O— (dioxanone ester moiety), —COCH 2 CH 2 CH 2 CH 2 CH 2 O— (caprolactone ester moiety), —CO(CH 2 ) m O—, where m is 2-4 or 6-24 and —COCH 2 O(CH 2 CH 2 O) n — where n is between 2-24; R′ is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; and p is 1-6. Multi-functional compounds and drug dimers, oligomers and polymers are also disclosed.

  所选化合物包括：DRUG-OH，DRUG-COOH和DRUG-NH2是具有生物活性的化合物；每个X独立选择自—CH2COO—（乙二酸酯基），—CH(CH3)COO—（乳酸酯基），—CH2CH2OCH2COO—（二氧杂环己酮酯基），—CH2CH2CH2CH2CH2COO—（己内酯酯基），—（CH2）yCOO—，其中y为2-4或6-24和—（CH2CH2O）zCH2COO—，其中z为2-24；每个Y独立选择自—COCH2O—（乙二酸酯基），—COCH(CH3)O—（乳酸酯基），—COCH2OCH2CH2O—（二氧杂环己酮酯基），—COCH2CH2CH2CH2CH2O—（己内酯酯基），—CO（CH2）mO—，其中m为2-4或6-24和—COCH2O（CH2CH2O）n—，其中n为2-24；R'为氢，苄基或烷基，所述烷基可以是直链或支链；p为1-6。还公开了多功能化合物和药物二聚体、寡聚体和聚合物。